- Home
- KRYS
KRYS
Krystal Biotech Inc.
as 12-17-2024 4:00pm EST
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 4.8B | IPO Year: | 2017 |
| Target Price: | $206.67 | AVG Volume (30 days): | 243.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $107.50 - $219.34 | Next Earning Date: | 11-04-2024 |
| Revenue: | $241,519,000 | Revenue Growth: | 2722.80% |
| Revenue Growth (this year): | 485.65% | Revenue Growth (next year): | 58.64% |
Stock Insider Trading Activity of Krystal Biotech Inc. (KRYS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Krishnan Krish S | KRYS | President and CEO | Dec 13 '24 | Sell | $167.11 | 50,000 | $8,240,023.05 | 1,555,960 |
Latest Krystal Biotech Inc. News
KRYS Breaking Stock News: Dive into KRYS Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Krystal Biotech Insider Sold Shares Worth $8,240,023, According to a Recent SEC Filing
Zacks
5 days ago
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
TipRanks
5 days ago
Krystal Biotech announces initial update for KB408, KB407
Zacks
6 days ago
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
GlobeNewswire
6 days ago
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
Argus Research
7 days ago
KRYS: What does Argus have to say about KRYS?
GlobeNewswire
9 days ago
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
Zacks
13 days ago
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?
Compare KRYS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRYS Krystal Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.